Comparison of microRNA expression levels in patients with schizophrenia before and after electroconvulsive therapy
![Thumbnail](/xmlui/themes/Mirage2//images/restricted.png)
Göster/ Aç
Erişim
info:eu-repo/semantics/closedAccessTarih
2024Yazar
Saglam, Nazife Gamze UstaDuz, Mehmet Bugrahan
Yilmaz, Seda Salman
Ozen, Mustafa
Balcioglu, Ibrahim
Üst veri
Tüm öğe kaydını gösterKünye
Saglam, N. G. U., Duz, M. B., Yilmaz, S. S., Ozen, M., & Balcioglu, I. (2024). Comparison of microRNA expression levels in patients with schizophrenia before and after electroconvulsive therapy. Psychiatric Genetics, 10-1097.Özet
ObjectiveExploring the role of microRNAs in the antipsychotic efficacy of electroconvulsive therapy (ECT) will contribute to understanding the underlying mechanism through which ECT exerts its therapeutic effects. The primary objective of this study was to identify microRNA alterations before and after ECT in patients with schizophrenia.MethodsWe compared microarray-based microRNA profiles in peripheral blood from eight patients with schizophrenia before and after ECT and eight healthy controls. Then, we aimed to validate selected differentially expressed microRNAs in 30 patients with schizophrenia following a course of ECT, alongside 30 healthy controls by using quantitative reverse-transcription PCR.ResultsMicroarray-based expression profiling revealed alterations in 681 microRNAs when comparing pre- and post-ECT samples. Subsequent quantitative reverse-transcription PCR analysis of the selected microRNAs (miR-20a-5p and miR-598) did not reveal any statistical differences between pre- and post-ECT samples nor between pre-ECT samples and those of healthy controls.ConclusionAs neuroepigenetic studies on ECT are still in their infancy, the results reported in this study are best interpreted as exploratory outcomes. Additional studies are required to explore the potential epigenetic mechanisms underlying the therapeutic efficacy of ECT.